Waseem Noor

Exploring new character benchmarks for today’s pharma executives, and whether they have the transformational traits to lead through change.

Outlining the new leadership and C-level roles of tomorrow needed to take on the disruption event on pharma's horizon.

Biopharma’s diversity commitment remains a work in progress but the benefits-in measurable ROI-are increasingly clear.

For those companies in this year's Pharm Exec Top 50, meeting the accelerating market demand for specialty products has become an acute strategic imperative.

Patent expiries dampen revenues for some of the biggest Big Pharma, but growth continues unabated for a few nimble "stealth" players moving steadily up the list.

Pharma industry alliances are increasingly critical to success. They are gaining on R&D in terms of importance, especially since many companies are falling short in their internal pipelines and need to look outside for promising compounds. Today, nearly two-thirds of the top 20 pharma and biotech companies have established alliance-management functions. These usually cover deals in the discovery, development, and marketing space.